Navigation Links
DURECT Reports Data From European Phase IIb Shoulder Study of POSIDUR™ (SABER™-Bupivacaine) and Amendment of the Nycomed Agreement
Date:2/9/2011

g candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.

DURECT Forward-Looking Statement

The statements in this press release regarding the potential uses and benefits of POSIDUR and our and our partners intended activities relating to POSIDUR, including our expectation of completing enrollment of the U.S. Phase III program in the first half of 2011 and the potential for Nycomed to continue funding development activities for POSIDUR are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements.  Potential risks and uncertainties include, but are not limited to, our ability to enroll the BESST trial in a timely basis, our and Hospira's ability to conduct and complete on-going clinical trials or to design and enroll additional clinical trials, if any, required for regulatory approval, failure of such clinical trials to produce intended results, Nycomed's evaluation of the results of the BESST trial and their decision whether to continue development and funding of POSIDUR, which is in their sole discretion, possible adverse events associated with the use of POSIDUR, delays and costs due to additional work or other requirements imposed by regulatory agencies for continued development, approval or sale of POSIDUR, our ability to complete the design, development, and manufacturing process development of POSIDUR, and to manufacture, commercialize and obtain marketplace acceptance of POSIDUR, and avoid infringing patents held by other parties and secure and defend patents of our own, and manage and obtain capital to fund our growth, operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q filed on November 4, 2010 under the heading "Risk Factors.


'/>"/>
SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
2. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
3. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
4. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
5. DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference
6. DURECT Corporation Invites You to Join Its Fourth Quarter 2009 Earnings Conference Call
7. DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory
8. DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial Results
9. DURECT to Present at the Cowen and Company Healthcare Conference
10. DURECT to Present at the Barclays Capital Global Healthcare Conference
11. DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , 30. September 2014 ... http://photos.prnewswire.com/prnh/20130430/LA01948LOGO Acutus ... ein minimal-invasives 3D-Herzkammer-Bildgebungs- und Dipoldichte-Mappingsystem in ... die zu komplexen Herzrhythmusstörungen einschließlich Vorhofflimmern ... Abschluss einer zusätzlichen Finanzierung über 26,2 ...
(Date:9/30/2014)... , Sept. 30, 2014   Acutus ... minimally invasive real-time 3D Cardiac Chamber Imaging and Dipole ... and / or sustain complex cardiac arrhythmias, including atrial ... to continue developing its imaging/mapping system as well as ... will allow Acutus Medical to complete work on the ...
(Date:9/30/2014)... 30, 2014 In 2011, approximately 5.1 million ... abused prescription pain relievers (e.g. opioids). 1 Clinical ... which entails the use of buprenorphine, buprenorphine/naloxone, naltrexone or ... important when developing and improving care management programs, according ... Prime Therapeutics LLC (Prime). ...
Breaking Medicine Technology:Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 2Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 3Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 3
... , , NEWPORT BEACH, Calif., ... data from a clinical study showing patient-specific cancer vaccines derived ... tolerated and resulted in impressive long-term survival rates in patients ... therapies. , , The study ...
... TARZANA, Calif., July 28 Less than two weeks ... Providence Tarzana Medical Center has applied the body-cooling treatment in ... , , Therapeutic hypothermia treatment, where cardiac ... nationwide to help prevent brain damage caused by a loss ...
Cached Medicine Technology:Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy 2Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy 3Treatment Shows Excellent Results for Providence Tarzana Patients Following Cardiac Arrest 2
(Date:9/30/2014)... R.I. [Brown University] Autism is no stranger to ... East African nation is access to clinical services, including ... diagnostic measure, for example, validated for use in Swahili, ... new study, however, researchers at Brown University and the ... approach that they implemented at two sites in the ...
(Date:9/30/2014)... NJ (PRWEB) September 30, 2014 ... and wellness, is opening another new medical specialty practice ... IMA Cardiology will be located within the ... Ziad Abbud and Dr. Isaac Tawfik of American Heart ... N.J. The new practice will offer Integrated Medicine Alliance ...
(Date:9/30/2014)... 2014 Glycodrive , one of ... to help maximize lean, strong muscle growth with a ... of glucose has caught the attention of Shane Michaels, ... behind Glycodrive is to help the body use carbohydrates ... “Carbs are essential in the muscle-building process, and Glycodrive ...
(Date:9/30/2014)... VisitandCare.com reports that revenue ... up more than 79 percent in 2014, marking five ... reported total revenue tripled for its entirety of partnered ... strategy has allowed them to partner with plastic ... comfort and privacy — with state-of-the-art surgical atmospheres aimed ...
(Date:9/30/2014)... A group of Americans is headed to ... that, left unchecked, could create a catastrophic, global pandemic. No, ... Africa. John Rogers, the Executive Director the Eugene Bell Foundation ... a disease most think mankind conquered long ago: tuberculosis. , ... is on the comeback in several countries - what’s especially ...
Breaking Medicine News(10 mins):Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2
... Use of estrogen alone did not increase lung cancer ... online August 13 in The Journal of the ... Health Initiative (WHI) trial, which consisted of several clinical ... previous hysterectomy taking combined estrogen plus progestin therapy had ...
... Reporter , FRIDAY, Aug. 13 (HealthDay News) -- When John D,Amato ... bottle of ibuprofen on the living room floor -- and one ... the pain-reliever container off the coffee table -- where D,Amato had ... pills. "My heart dropped through the floor," he said of ...
... influential medical centers to adopt electronic medical records helps ... Management Insights feature in the current issue of ... for Operations Research and the Management Sciences (INFORMS)., "Social ... Medical Records in U.S. Hospitals" is by Corey M. ...
... over the past 25 years has not translated into ... problems with study design and interpretation, as well as ... 12 in The Journal of the National Cancer ... defines a biomarker as "a characteristic that is objectively ...
... hereditary cancer syndrome may have a role in the regulation of ... the August 15 issue of Genes & Development , a ... called merlin, encoded by the NF2 (neurofibromatosis type 2) gene, controls ... two major types of liver cells. "We found that ...
... HealthDay Reporter , THURSDAY, Aug. 12 (HealthDay News) ... new study finds that many heart patients aren,t all ... in Australia discovered that patients more often preferred boring ... pressure. "Fifty grams of dark chocolate [roughly one ...
Cached Medicine News:Health News:Estrogen not associated with lung cancer incidence and mortality among postmenopausal women 2Health News:Human Meds Are Pets' Biggest Poisoning Danger 2Health News:Human Meds Are Pets' Biggest Poisoning Danger 3Health News:Speed electronic medical record adoption via key medical centers, says Management Science 2Health News:The cancer biomarker conundrum: Too many false discoveries 2Health News:Merlin protein found to control liver stem cells, prevent tumor development 2Health News:Many Patients Say 'No' to Chocolate As Medicine 2Health News:Many Patients Say 'No' to Chocolate As Medicine 3
... elbow, wrist, and hand. Appliance holding patient's ... the opposite shoulder. Abduction can be set ... attaches to pillow wedge at 90 angle. ... along length of arm. Humerus and wrist ...
... Combining the therapeutic benefits of controlled compression ... swelling, and pain. The anatomically designed cuff ... Shoulder Cryo/Cuff can be ordered with an ... larger chest circumferences.,All Cryo/Cuffs can be ordered ...
... comfortable pre-fabricated orthosis is designed for ... third humeral diaphyseal fractures. The lightweight ... soft tissue compression for optimal control ... range-of-motion of both the shoulder and ...
... to treat or help prevent lower ... hip displasia, foot drop, contractures and pressure ... lining provides a comfortable wicking interface for ... easily rotated and locked into a vertical ...
Medicine Products: